High-clarity aqueous concentrates of 4-hexylresorcinol

Details High-clarity aqueous concentrates of 4-hexylresorcinol High-clarity aqueous concentrates of 4-hexylresorcinol

2009-10-02

2011-12-27

Thomas, Timothy (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

Reexamination Certificate

active

08084504

ABSTRACT:
The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.

REFERENCES:
patent: 1649670 (1927-11-01), Dohme et al.
patent: 3193507 (1965-07-01), Jacobs
patent: 4093667 (1978-06-01), Starks
patent: 4337370 (1982-06-01), Takisawa et al.
patent: 4959393 (1990-09-01), Torihara et al.
patent: 5705145 (1998-01-01), Miklean et al.
patent: 6852310 (2005-02-01), Harichian et al.
patent: 6863897 (2005-03-01), Love et al.
patent: 6869598 (2005-03-01), Love et al.
patent: 7468464 (2008-12-01), Harichian et al.
patent: 2004/0109832 (2004-06-01), Harichian et al.
patent: 2006/0019002 (2006-01-01), Xue
patent: 2006/0120975 (2006-06-01), Scheri et al.
patent: 2006/0210497 (2006-09-01), Harichian et al.
patent: 2006/0264497 (2006-11-01), Zeligs
patent: 2006/0269504 (2006-11-01), James
patent: 2006/0292184 (2006-12-01), Richardson et al.
patent: 2007/0196523 (2007-08-01), Koganov
patent: 2008/0131382 (2008-06-01), Harichian et al.
patent: 2008/0260671 (2008-10-01), De La Torre et al.
patent: 2008/0286217 (2008-11-01), Chaudhuri
patent: 2008/0305059 (2008-12-01), Chaudhuri
patent: 2008/0317887 (2008-12-01), Mitchell et al.
patent: 2010/0124539 (2010-05-01), Hanson
patent: 2010/0189669 (2010-07-01), Hakozaki
patent: 101 18 894 (2002-10-01), None
patent: 1 250 908 (2002-10-01), None
patent: 1 974 773 (2008-10-01), None
patent: 1987811 (2008-11-01), None
patent: 2 045 297 (2009-04-01), None
patent: 2438999 (2007-12-01), None
patent: 2000-327557 (2000-11-01), None
patent: 4004182 (2000-11-01), None
patent: 2001 302505 (2001-10-01), None
patent: 2004-107210 (2004-04-01), None
patent: 2006-327965 (2006-12-01), None
patent: 2007254412 (2007-10-01), None
patent: 2008-184431 (2008-08-01), None
patent: 2009084164 (2009-04-01), None
patent: WO 03/082231 (2003-10-01), None
patent: WO 2004/052330 (2004-06-01), None
patent: WO 2006/097223 (2006-09-01), None
patent: WO 2006/128032 (2006-11-01), None
patent: WO 2008/143761 (2008-11-01), None
patent: WO 2008153629 (2008-12-01), None
Ochsner et al.; “Prediction of Solubility in Nonideal Multicomponent Systems Using the UNIFAC Group Contribution Model”; 1985; Journal of Pharmaceutical Sciences; 74(6): 634-637.
Xia et al.; “Dehydration of ethyl acetate-water mistures using PVA/ceramic composite pervaporation membrane”; 2011; Separation and Purification Technology; 77: 53-59.
Hall et al.; “The Solubilization of Hexylresorcinol by an Anionic-Nonionic Surfactant Mixture”; 1966; Amer. Jour. Pharm.; 138(6): 245-8.
V. Cenizo, et al., “LOXL as a Target to Increase the Elastin Content in Adult Skin: A Dill Extract Induces the LOXL Gene Expression,” Experimental Dermatology; 2006, vol. 15(8), 574-581.
Hamamoto, et al., “Inhibitory effect of azelastine, a potent antiallergic agent, on release of tumor necrosis factor-a from activated human peripheral blood mononuclear cells and U937 cells,” Exp Dermatol, 1993: 2: p. 231-235.
M. Herrmann, et al., “Blackberry Leaf Extract A New Anti-Aging Active,” SOFW Journal; 2006, vol. 132(4), 42-46.
J. L Lamaison, et al., “Tannin Content and Elastase Inhibiting Activity in the Rosaceae Family,” Ann. Pharmaceutiques Francaises; 1990, vol. 48, 335-340.
Y. Lin, et al., “Theaflavin-3,3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-κB in macrophages,” European Journal of Pharmacology, vol. 367, No. 2-3, Feb. 1999, p. 379-388, XP009090023.
R. Liu, et al., “Retinoic Acid Increases Elastin in Neonatal Rat Lung Fibroblast Cultures,” Am. Physiol, Society, 1993, 265(5pt. 1):L430-437.
X. Liu, et al., “Elastic Fiber Homeostasis Requires Lysyl Oxidase-like 1 Protein,” Nature Genetics ; 2004, vol. 36(2), 178-182.
Int'l. Search Report for Application No. PCT/US2010/051080, dated Dec. 6, 2010.
Database WPI, Week 200930, Thomson Scientific, London, GB; AN 2009-H70662 XP 002635472, JP 2009 084164 A (Septem Soken KK) Apr. 23, 2009, Abstract.
Database WPI, Week 200849, Thomson Scientific, London, GB; AN 2008-H65100 XP002635473, JP 2007 254412 A (Kurarray Co Ltd) Oct. 4, 2007, Abstract.
Database WPI, Week 200223, Thomson Scientific, London, GB; AN 2002-174418 XP002635474, JP 2001 30205A (Kurarray Co Ltd) Oct. 31, 2001, Abstract.
EP Search Report for Application No. EP 10251712.5 dated May 6, 2011.

Affiliated with

Also associated with

Rating

High-clarity aqueous concentrates of 4-hexylresorcinol does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High-clarity aqueous concentrates of 4-hexylresorcinol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-clarity aqueous concentrates of 4-hexylresorcinol will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4307418